Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Narcolepsy01:07

Narcolepsy

304
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
304
Sleep-Wake Cycles01:24

Sleep-Wake Cycles

2.4K
Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and  rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
2.4K
REM Sleep Behavior Disorder01:15

REM Sleep Behavior Disorder

912
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
912
Seizures: Classification01:13

Seizures: Classification

1.0K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.0K
Restless Leg Syndrome and Night Terrors01:27

Restless Leg Syndrome and Night Terrors

339
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
339
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

424
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
424

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hemorrhagic Transformation Mediates Stress Hyperglycemia Effect on Functional Outcome in Minor Ischemic Stroke.

Journal of the American Heart Association·2026
Same author

Clinical markers of disease progression in the prodromal to overt alpha-synucleinopathy continuum.

Brain : a journal of neurology·2026
Same author

Ketogenic Diet-Based Therapy for Fatigue in Patients with Multiple Sclerosis.

Nutrients·2026
Same author

Genetic associations between post-traumatic stress disorder and REM-sleep behavior disorder.

NPJ Parkinson's disease·2026
Same author

Response to letter to the editor on the article "AQP4 levels in CSF correlate with clinical severity in iNPH patients: A pilot study".

Journal of the neurological sciences·2026
Same author

Timing of insertable cardiac monitor implantation after embolic stroke of undetermined source and its impact on atrial fibrillation detection: A target trial emulation analysis.

International journal of stroke : official journal of the International Stroke Society·2026

Related Experiment Video

Updated: Nov 22, 2025

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

618

Orgasmolepsy in Narcolepsy Type 1 Responsive to Pitolisant: A Case Report.

Gaia Pellitteri1,2, Pierluigi Dolso1, Mariarosaria Valente1,2

  • 1Clinical Neurology Unit, Department of Neurosciences, Udine University Hospital, Udine, Italy.

Nature and Science of Sleep
|January 7, 2021
PubMed
Summary

Pitolisant effectively controlled orgasmolepsy, a rare narcolepsy type 1 symptom, in a young male patient. This highlights pitolisant

Keywords:
NT1cataplexynarcolepsy treatmentsexual dysfunction

More Related Videos

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
04:51

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

9.9K
Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

7.7K

Related Experiment Videos

Last Updated: Nov 22, 2025

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

618
Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
04:51

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

9.9K
Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
10:41

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia

Published on: September 12, 2020

7.7K

Area of Science:

  • Neurology
  • Sleep Medicine
  • Pharmacology

Background:

  • Narcolepsy type 1 (NT1) is a chronic neurological disorder characterized by excessive daytime sleepiness and cataplexy.
  • Orgasmolepsy, cataplexy triggered by orgasm, is an underreported and poorly understood manifestation of NT1.
  • Current treatment options for NT1 symptoms, particularly orgasmolepsy, are limited.

Observation:

  • A young male patient with NT1 experienced generalized cataplexy attacks during sexual intercourse (orgasmolepsy).
  • This specific symptom of NT1 was not well-documented in existing medical literature.
  • The patient's condition presented a unique challenge for clinical management.

Findings:

  • Pitolisant, a selective histamine H3 receptor inverse agonist/antagonist, was administered to the patient.
  • Satisfactory control of orgasmolepsy attacks was achieved with pitolisant treatment.
  • This represents the first reported instance of pitolisant's efficacy in managing orgasmolepsy in NT1.

Implications:

  • Pitolisant may be a viable therapeutic option for orgasmolepsy in narcolepsy type 1 patients.
  • Clinicians should proactively screen NT1 patients for sexual disturbances like orgasmolepsy.
  • Considering pitolisant or sodium oxybate may be preferable to antidepressants due to potential sexual side effects.